TITLE

Role of sunitinib and SU12662 on dermatological toxicities in metastatic renal cell carcinoma patients: in vitro, in vivo, and outcomes investigation

AUTHOR(S)
Teo, Yi; Chong, Xue; Chue, Xiu; Chau, Noan; Tan, Min-Han; Kanesvaran, Ravindran; Wee, Hwee; Ho, Han; Chan, Alexandre
PUB. DATE
February 2014
SOURCE
Cancer Chemotherapy & Pharmacology;Feb2014, Vol. 73 Issue 2, p381
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Purpose: Sunitinib commonly exhibits dose-limiting dermatological toxicities (DTs) that adversely affect health-related quality of life (HRQoL). Pharmacological activity of sunitinib is attributed to sunitinib and an equipotent, active metabolite, SU12662. The objective of this study is to compare the dermatotoxic potential of sunitinib and SU12662, and changes in HRQoL due to DTs. Methods: A prospective cohort study was conducted on metastatic renal cell carcinoma patients. Plasma drug concentrations were determined by high-performance liquid chromatography. DTs were graded by Common Terminology Criteria for Adverse Events. HRQoL of patients with hand-foot skin reaction (HFSR) was assessed by the hand-foot syndrome-specific quality-of-life questionnaire (HFS-14). In addition, the ICs of both compounds were determined with HaCaT keratinocytes. Results: Sunitinib was more dermatotoxic in vitro, with a lower IC than SU12662 (23.33 vs. 35.32 μM, p = 0.02). Similar results were observed in vivo, with higher sunitinib-to-SU12662 ratio in patients with pruritus, than patients without pruritus ( p = 0.04). Higher HFS-14 scores were observed in patients with higher HFSR grade and in those with both hands and feet affected, indicating poorer HRQoL. Conclusions: Sunitinib may be more dermatotoxic than SU12662 from both in vivo and in vitro evidences. Therefore, appropriate management of DTs may be essential, especially in patients with a reduced sunitinib metabolising ability.
ACCESSION #
94232536

 

Related Articles

  • Prospective Comparison of Sorafenib and Sunitinib for Second-Line Treatment of Cytokine-Refractory Kidney Cancer Patients. Herrmann, Edwin; Bierer, Stefan; Gerss, Joachim; Köpke, Thomas; Hertle, Lothar; Wülfing, Christian // Oncology;2008, Vol. 74 Issue 3/4, p216 

    Objectives: It was the aim of this study to investigate the clinical differences between the tyrosine kinase inhibitors (TKIs) sorafenib and sunitinib as second-line treatment for cytokine-refractory kidney cancer patients. Methods: Twenty consecutive patients received continuous treatment of...

  • A Pooled Analysis of Sequential Therapies with Sorafenib and Sunitinib in Metastatic Renal Cell Carcinoma. Stenner, Frank; Chastonay, Rahel; Liewen, Heike; Haile, Sarah R.; Cathomas, Richard; Rothermundt, Christian; Siciliano, Raffaele D.; Stoll, Susanna; Knuth, Alexander; Buchler, Tomas; Porta, Camillo; Renner, Christoph; Samaras, Panagiotis // Oncology;Jul2012, Vol. 83 Issue 2, p333 

    Objective: To evaluate the optimal sequence for the receptor tyrosine kinase inhibitors (rTKIs) sorafenib and sunitinib in metastatic renal cell cancer. Methods: We performed a retrospective analysis of patients who had received sequential therapy with both rTKIs and integrated these results...

  • Cutaneous events. Jesitus, John // Dermatology Times;Nov2008, Vol. 29 Issue 11, p90 

    The article reports on the case a 66-year-old Caucasian male patient treated with tyrosine kinase inhibitor sorafenib for his renal cell carcinoma (RCC). The patient has no history of skin cancer, yet, he has developed squamous cell carcinomas (SCCs) during the treatment period. Sorafenib was...

  • Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives. Narayan, Vivek; Haas, Naomi Balzer // International Journal of Nephrology & Renovascular Disease;Mar2016, Vol. 9, p65 

    Background: Axitinib is a next-generation, selective tyrosine kinase inhibitor targeting the vascular endothelial growth factor receptors. It is approved for the treatment of metastatic renal cell carcinoma (mRCC) based on a demonstrated progression-free survival advantage over sorafenib in the...

  • A population-based study examining the effect of tyrosine kinase inhibitors on survival in melastatic renal cell carcinoma in Alberta and the role of nephrectomy prior to treatment. Warren, Mark; Venner, Peter M.; North, Scott; Cheng, Tina; Venner, Chris; Ghosh, Sunita; Venner, Allison A.; Finch, Daygen // Canadian Urological Association Journal;Aug2009, Vol. 3 Issue 4, p281 

    Background: We performed a retrospective population-based study to assess the impact of tyrosine kinase inhibitors (TKIs) on overall survival (OS) in patients treated for metastatic renal cell carcinoma (mRCC) in Alberta, Canada and to assess the impact of nephrectomy on OS in patients treated...

  • Pazopanib better QOL than sunitinib in mRCC.  // PharmacoEconomics & Outcomes News;9/21/2013, Issue 687, p10 

    The article discusses a study published in the August 22, 2013 issue of the "New England Journal of Medicine" that compared the quality of life (QOL) between pazopanib and sunitinib tyrosine kinase inhibitors for the treatment of patients with metastatic renal-cell carcinoma (mRCC).

  • Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib. Riesenbeck, L.; Bierer, S.; Hoffmeister, I.; Köpke, T.; Papavassilis, P.; Hertle, L.; Thielen, B.; Herrmann, E. // World Journal of Urology;Dec2011, Vol. 29 Issue 6, p807 

    Purpose: To investigate prognostic markers in patients with metastatic renal cell carcinoma (mRCC) undergoing treatment with the tyrosine kinase inhibitors (TKIs) sorafenib (So) or sunitinib (Su). Patients and methods: Eighty-three patients with mRCC, who were treated at our institution between...

  • Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network.  // Current Medical Literature: Kidney Cancer;Mar2011, Vol. 3 Issue 1, p31 

    The article discusses a Juvenile Renal Cell Carcinoma (RCC) network study on the effect of mammalian target of rapamycin (mTOR) and tyrosine kinase inhibitors on Xp11 translocation RCC. Patients who had received metastatic disease treatment administered first to fourth-line treatments, which...

  • Vitiligo: A new side effect of everolimus therapy for metastatic renal cell carcinoma. Cacciapuoti, Sara; Masarà, Anna; Mariano, Maria; Cameli, Norma; Fabbrocini, Gabriella // Australasian Medical Journal;2017, Vol. 10 Issue 10, p898 

    Patients with metastatic renal cell carcinoma (mRCC) have always had a poor prognosis. Recently new targeted drugs were developed. A 73-year-old female patient affected from mRCC was assessed at our Department. She underwent before a multitargeted tyrosine kinase inhibitor (TKI) therapy, but she...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics